

INTERNATIONAL SEARCH REPORT

Inte
al Application No
PCT/US2004/004765

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D239/22	A61K31/513	C07C225/18	C07D231/06	C07D239/26
	C07D281/10	A61K31/135	A61K31/415	A61K31/505	A61K31/554

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CROSTON G E ET AL: "Discovery of the First Nonpeptide Agonist of the GPR14/Urokinase-II Receptor: 3-(4-Chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-7954)" JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 23, 7 November 2002 (2002-11-07), pages 4950-4953, XP001153553 ISSN: 0022-2623 page 4951, column 1, scheme 1 page 4951, column 1, last paragraph</p> <p style="text-align: center;">-/-</p>	1,6-13, 19-33

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the International search

16 August 2004

Date of mailing of the International search report

25.11.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

Inte al Application No

PCT/US2004/004765

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	BERTOZZI F ET AL: "A Combinatorial Scaffold Approach Based upon a Multicomponent Reaction" ORGANIC LETTERS, vol. 5, no. 9, 1 May 2003 (2003-05-01), pages 1551-1554, XP002292429 page 1553, scheme 2, compound 3 -----	1,6-13, 19-33

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 25-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see annex

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 25–32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 6-12 (all partly), 13, 19-33 (all partly)
the compounds of the present formula I

2. claims: 2, 6-12 (all partly), 17-33 (all partly)
the compounds of the present formula II

3. claims: 3, 6-12 (all partly), 14, 17-33 (all partly)
the compounds of the present formula III

4. claims: 4, 6-12 (all partly), 15, 19-33 (all partly)
the compounds of the present formula IV

5. claims: 5, 6-12 (all partly), 16, 17-33 (all partly)
the compounds of the present formula V
